Syndax Pharmaceuticals Inc Aktie News

NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, as well as members of the Syndax management team, will participate in the following upcoming investor conferences: UBS Global Healthcare Conference 2025 with a fire...

NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its third quarter 2025 financial results and provide a business update on Monday, November 3, 2025.

Syndax Pharmaceuticals received expanded FDA approval for Revuforj, tripling its addressable AML patient population despite a boxed safety warning. Revumenib remains the only FDA-approved menin inhibitor for both KMT2A-rearranged and NPM1-mutated AML, offering a defensible niche and first-mover advantage. SNDX trades at a premium valuation, reflecting high expectations for commercial ramp; stro...

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX ) Discusses FDA Approval of Revuforj for Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia October 24, 2025 2:30 PM EDT Company Participants Sharon Klahre - Vice President of Investor Relations & Communications Michael Metzger - CEO & Director Nicholas Botwood - Head of Research & Development and Chief Medical Officer Steven Closter - Chief Com...

– First and only therapy FDA approved in both R/R acute myeloid leukemia (AML) with an NPM1 mutation and R/R acute leukemia with a KMT2A translocation –

The biotech sector has underperformed the market for many years now, but there are reasons to be optimistic about this area of the market. Many biotech/biopharma stocks also make good covered call trade candidates due to the liquidity and lucrativeness of the option premiums against these equities. Stocks had their biggest decline last Friday since the first half of April due to escalating trad...

How to trade and invest in the biotech space, according to ROTY Biotech Community's Jonathan Faison. Favoring late-stage, commercial-stage companies with clear paths to profitability and strong sales ramp potential.

NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on October 1, 2025 the Company granted inducement awards to purchase up to 138,900 shares of common stock to 10 new employees under the Company's 2023 Inducement Plan. The stock options will vest over four yea...